Full-year revenue declined 6.1% due to weaker Healthcare sales, but gross margin improved to 56.0% and net profit rose 16.3% to S$265.5m, supported by higher dividend income and cost management. Strategic investments remain a key asset.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.